Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.

Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.

Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.

Tofacitinib was more effective than methotrexate for treating alopecia areata.

Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.

Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.

Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.

Hair samples can reliably monitor tacrolimus levels in kidney transplant patients.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Targeting JAK-STAT1 can reduce inflammation and promote hair growth in conditions linked to EGFR deficiency.

Topical tofacitinib may help regrow hair in children with alopecia totalis.

Patients with alopecia areata using Janus kinase inhibitors are not following lab monitoring guidelines.

Stopping and restarting JAK inhibitors during pregnancy in women with alopecia areata leads to hair loss and regrowth, with most pregnancies resulting in healthy babies.

Bimekizumab effectively treats scalp cellulitis and improves quality of life.

Renal transplant patients on tacrolimus and sirolimus may develop acne keloidalis nuchae.

Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.

Baricitinib is effective and safe for treating severe alopecia areata.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Ruxolitinib can cause a delayed skin reaction on the nose.

Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.

COVID-19 vaccination may cause kidney inflammation, treatable with steroids and Cellcept.

Baricitinib is effective for severe alopecia areata but has some side effects.

The treatment significantly improved lymphocytic cicatricial alopecia symptoms in most patients.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.

The rash resolved after stopping ponatinib.